Negative
22Serious
Neutral
Optimistic
Positive
- Total News Sources
- 3
- Left
- 1
- Center
- 2
- Right
- 0
- Unrated
- 0
- Last Updated
- 3 days ago
- Bias Distribution
- 67% Center


Cencora Raises 2025 Profit Forecast Amid Strong Specialty Drug Demand
Cencora, formerly known as AmerisourceBergen, reported a significant revenue increase of 12.8% year-over-year for the first quarter of fiscal 2025, reaching $81.5 billion, driven by strong sales of specialty medicines and GLP-1 drugs. The company raised its adjusted earnings per share (EPS) guidance for the year to a range of $15.25 to $15.55, reflecting robust performance and strategic acquisitions, including Retina Consultants of America. Despite a decrease in GAAP diluted EPS due to operating costs, Cencora's adjusted EPS of $3.73 exceeded analyst expectations of $3.50. The U.S. healthcare solutions segment saw a notable 14% revenue gain, bolstered by increased demand for medications addressing complex conditions. Cencora's focus on specialty services and customer-centric strategies has positioned it favorably in the healthcare market. Analysts remain optimistic about Cencora's growth potential, with projected revenue growth of 8% to 10% for the full fiscal year.



- Total News Sources
- 3
- Left
- 1
- Center
- 2
- Right
- 0
- Unrated
- 0
- Last Updated
- 3 days ago
- Bias Distribution
- 67% Center
Negative
22Serious
Neutral
Optimistic
Positive
Related Topics
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Gift Subscriptions
The perfect gift for understanding
news from all angles.